Yeleswaram Krishnaswamy 4

What Happened
Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), received a grant of a derivative award covering 120,000 shares on 2026-02-02. The reported acquisition price is $0.00 (derivative), so no cash was paid in this filing; the award will vest and become exercisable over time rather than representing immediately tradable shares.

Key Details

• Transaction date: 2026-02-02; filing date (Form 4): 2026-02-04 (timely filing).
• Amount granted: 120,000 shares (reported as a derivative acquisition) at $0.00.
• Shares owned after transaction: Not specified in the reported data.
• Footnote: F1 — the shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments beginning January 1, 2026, subject to continued service.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context
This is a time‑based equity award (derivative) that vests monthly over four years; it is not an immediate open‑market purchase or sale. Such grants are common as part of executive compensation and do not by themselves indicate an immediate change in insider sentiment. The reported value is $0.00 at grant; any future economic value will depend on the company’s stock price and the award’s exercise/settlement terms.